Process to inhibit binding of the integrin .alpha..sub.4 62 .sub.1 to VCAM-1 or fibronectin and linear peptides therefor
US5510332A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 7, 1994 |
| Grant date | Apr 23, 1996 |
| Priority date | — |
| Expiry date | Jul 7, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses .alpha..sub.4 .beta..sub.1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.